Sanofi — Director's Dealing 2019

Jul 18, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Fulcrum Therapeutics, Inc. (FULC)
CIK: 0001680581
Period of Report: 2019-07-17

Reporting Person: Sanofi (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock (par value, $0.001)	$		Common Stock (464285)		Indirect

Footnotes

F1: Sanofi is the beneficial owner of Series B Preferred Stock of the Issuer through its wholly owned subsidiary Aventis Inc.

F2: The Series B Preferred Stock is convertible on a seven-for-one basis into the number of shares of Common Stock of the Issuer as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the initial public offering of the Issuer without payment or further consideration. . The shares have no expiration date.